Cargando…
Designer antiandrogens join the race against drug resistance
By using in silico models of the complexes formed by analogues of a cancer drug and its receptor, it may be possible to strategically redesign existing drugs and win the race against mutations that lead to drug resistance in prostate cancer.
Autores principales: | Josan, Jatinder S, Katzenellenbogen, John A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3622176/ https://www.ncbi.nlm.nih.gov/pubmed/23580166 http://dx.doi.org/10.7554/eLife.00692 |
Ejemplares similares
-
Overcoming mutation-based resistance to antiandrogens with rational drug design
por: Balbas, Minna D, et al.
Publicado: (2013) -
Critical race theory in medicine
por: Zewude, Rahel, et al.
Publicado: (2021) -
GREB1 amplifies androgen receptor output in human prostate cancer and contributes to antiandrogen resistance
por: Lee, Eugine, et al.
Publicado: (2019) -
Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer
por: Wu, Meng, et al.
Publicado: (2023) -
The past, present and future of race and colonialism in medicine
por: Amster, Ellen J.
Publicado: (2022)